论文部分内容阅读
目的评价尿激酶(UK)溶栓治疗心源性脑栓塞的临床疗效及安全性。方法采用国产尿激酶100～150万U静脉滴注,对42例发病在6h以内的心源性脑栓塞患者进行溶栓治疗,比较治疗前后神经功能缺损评分(NFDI)。另设40例普通病例作对照组。结果溶栓后2hNFDI为20.12±2.65,较溶栓治疗前26.78±3.42明显减少(P<0.001),治疗后21d溶栓组NFDI为18.21±3.16,明显低于对照组,治疗后21d溶栓治疗组的治愈率、显效率、总有效率分别为33.3%、69%、88.1%,显著高于对照组(15%、32.5%、50%),两组比较有显著差异(P<0.05)。结论在严格掌握溶栓治疗适应症的基础上应用尿激酶静脉溶栓治疗心源性脑栓塞疗效好、并发症少。
Objective To evaluate the clinical efficacy and safety of urokinase (UK) thrombolytic therapy for cardioembolic stroke. Methods Thrombolytic therapy was performed in 42 patients with cardioembolic cerebral infarction within 6h after intravenous infusion of 10-1.5 million U.U.U., and the neurological deficit score (NFDI) was compared between the two groups. Another 40 cases of common cases for the control group. Results The level of NFDDI was 20.12 ± 2.65 at 2h after thrombolytic therapy, which was significantly lower than that before thrombolytic therapy (26.78 ± 3.42, P <0.001). After 21 days of treatment, the NFDI in thrombolytic group was 18.21 ± 3.16, significantly lower than that in control group The cure rate, effective rate and total effective rate were 33.3%, 69% and 88.1% respectively, which were significantly higher than those in the control group (15%, 32.5%, 50%). There was significant difference between the two groups (P <0.05). Conclusion The strict control of thrombolytic therapy based on the application of intravenous thrombolytic therapy of urokinase cardioembolism effective and less complications.